Aprogen, Inc stock analysis
Want to see KR:007460 full AI Analyst Report?
Aprogen, Inc (007460) Stock Price & Analysis
007460 Stock Chart & Stats
- Day’s Range
- KRW 1,674.00 - KRW 1,759.00
- 52-Week Range
- KRW 1,615.00 - KRW 14,070.00
- Previous Close
- KRW 1,720.00
- Volume
- N/A
- Average Volume (3M)
- 101.51K
- Market Cap
- KRW 8.36B
- Enterprise Value
- KRW 546.73B
- Total Cash (Recent Filing)
- KRW 43.16B
- Total Debt (Recent Filing)
- KRW 181.45B
- Price to Earnings (P/E)
- ―
- Beta
- 0.28
- Next Earnings
- Mar 29, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Recent revenue growth indicates that Aprogen is expanding its commercial or development-related activity despite weak profitability. If the company can sustain this top-line momentum, it may provide a broader base over which operating efficiencies and future biologic product contributions can develop.
Biologic Medicines Focus
A focus on biologics, biosimilars, and antibody-based therapeutics places Aprogen in markets where specialized development and production capabilities are important. This business orientation can support durable relevance as healthcare demand increasingly includes biologic treatment options.
Recombinant Protein And Cell-Culture Capabilities
Recombinant protein and cell-culture technologies, combined with related production capabilities, give Aprogen an established technical foundation for its biologics pipeline. These capabilities can support repeated development and manufacturing efforts across multiple therapeutic programs over time.
Bears Say
Persistent Deep Losses
Persistent, deep losses show that revenue growth is not currently translating into a viable earnings base. Continued negative operating and net results may restrict internal reinvestment, reduce financial resilience, and require the company to improve economics before growth can create shareholder value.
Sustained Cash Burn
Consistently negative operating and free cash flow means Aprogen is not funding operations and investment from internally generated cash. The worsening TTM free-cash-flow deficit increases dependence on external funding and can constrain the pace or sustainability of future development activity.
Rising Leverage And Weaker Capital Cushion
The sharp increase in debt-to-equity and decline in equity materially weaken Aprogen's capital cushion. Higher leverage can limit financial flexibility, increase pressure to fund obligations while losses continue, and make it harder to absorb setbacks in development or production.
007460 FAQ
What was Aprogen, Inc’s price range in the past 12 months?
What is Aprogen, Inc’s market cap?
When is Aprogen, Inc’s upcoming earnings report date?
How were Aprogen, Inc’s earnings last quarter?
Is Aprogen, Inc overvalued?
Does Aprogen, Inc pay dividends?
What is Aprogen, Inc’s EPS estimate?
How many shares outstanding does Aprogen, Inc have?
What happened to Aprogen, Inc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Aprogen, Inc?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Aprogen, Inc
Founded in 1971 and headquartered in Seongnam-si, South Korea, Aprogen Medicines Inc. (formerly Aprogen KIC Inc. until its name change in April 2021) specializes in the design, manufacture, and maintenance of plant facilities. Their services cater to crucial sectors including steelwork, petrochemistry, shipbuilding, power generation, and liquefied natural gas (LNG) base industries. The company also provides thermal and cold spray services, a diverse range of clad products such as rolls, plates, wear plates, pipes, and fittings, along with plasma transferred arcs. Furthermore, Aprogen Medicines Inc. offers the Nukon system, a specialized heat-preservation solution vital for ensuring the safe operation of internal piping within pressurized water reactor power plant containment buildings. They are also a supplier of Foamglas, a cellular glass insulation product, and undertake fireproof insulation works for furnaces and boilers, notably at POSCO.
- Sector
- General
- Industry
- Conglomerates
- CEO
- Jaeseob Kim
- Employees
- 311
- Website
- www.aprogen.com
- Address
- Hallasigma valley (Sangdaewon-dong), Seongnam-si, GY, 13215, KR
Aprogen, Inc (007460) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| KR:068330ilShinbiobase Co., Ltd. |



